Is this the same product that HealthSport was developing? Sure seems similar..... Plus there's the M.E. Hank Durschlag connection.
Double Eagle Holdings, Ltd. - FORM 10-K - EX-31.1 - January 6, 2011www.faqs.org/sec-filings/110106/Double.../v207458_ex31-1.htmCached
Jan 6, 2011 – SARBANES-OXLEY ACT OF 2002. I, M.E. "Hank" Durschlag, certify that: ... /s/ M.E. "Hank" Durschlag. Chief Executive Officer ...
Healthsport, Inc. - faqs.orgwww.faqs.org/sec-filings/091116/...Inc_10.../c92691exv31w1.htm
Nov 16, 2009 – I, M.E. Hank Durschlag, certify that: 1. I have reviewed this quarterly report on Form 10-Q of HealthSport, Inc.; ...
HealthSport is a technology company specializing in the development and manufacture of proprietary, oral thin film products. We are dedicated to improving the quality of life through innovative delivery technologies for pharmaceutical, nutraceutical and veterinary products.
A pioneer in the industry, we were the first company to deliver a drug active via oral thin film with the development of the Chloraseptic® Sore Throat Relief Strips® in June 2003. Utilizing our patent pending, bi-layer technology, we have proceeded to develop and launch an impressive variety of dietary supplement and over the counter pharmaceutical thin film products, including those containing vitamins, minerals, electrolytes, sleep aids, caffeine, antioxidants and various over-the-counter drug actives.
Our thin film, which for most applications is similar in size and shape to a postage stamp, dissolves rapidly and utilizes patent pending “bi-layer” technology and other novel processes, including proprietary micro-encapsulation methods to mask the taste of actives in the film products. The result of this superior technology is higher quality, more stable products that support a platform capable of carrying larger product volumes and a more diverse array of active ingredients. We believe these qualities render our thin film effective, easy to use and suited for a multitude of consumer products in both the dietary supplement and pharmaceutical arenas.
We currently manufacture and distribute a number of nutritional supplement products formulated to contain electrolytes, vitamins, melatonin, caffeine, and other supplements. We are also currently conducting research and development related to future potential products that will contain over-the-counter and prescription drug actives. Based on our existing portfolio of intellectual property, we anticipate significant potential opportunities to develop business with pharmaceutical companies. We believe our thin film technology can be used to create new, more effective drug products that should enjoy strong physician, patient and consumer acceptance. One unique potential opportunity involves using our technology to enable pharmaceutical companies to better manage the life cycle of their products. By combining our thin film delivery technology with existing drugs, we may be able to strategically differentiate existing or soon-to-be generic drugs from potential generic competitors or provide branded prescription products with additional patent protection or exclusivity in the marketplace.
We intend to continue to make revolutionary advances in producing high-quality products that successfully address medical and consumer health needs while minimizing the risk of side effects.
